Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Rhea-AI Summary

Repligen (NASDAQ:RGEN) opened a new Repligen Training & Innovation Center (RTIC) at its OPUS pre-packed chromatography manufacturing site in Breda, Netherlands, on April 15, 2026. The Breda RTIC is the company’s third global center, joining Waltham and Tokyo, and showcases upstream, downstream, analytical and fluid management technologies.

The facility offers product exhibits, demonstration areas, hands-on workshops and pre-/post-sales customer support to strengthen global customer proximity and technical training.

AI-generated analysis. Not financial advice.

News Market Reaction – RGEN

+3.24%

1 alert

+3.24% News Effect

On the day this news was published, RGEN gained 3.24%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Global RTIC count: 3 centers Breda opening date: April 15

2 metrics

Global RTIC count 3 centers Third Repligen Training & Innovation Center, after Waltham and Tokyo

Breda opening date April 15 Date of Breda RTIC opening event with key biopharma and CDMO customers

Market Reality Check

Price: $102.87 Vol: Volume 649,670 is 0.79x t...

normal vol

$102.87 Last Close

Volume Volume 649,670 is 0.79x the 20-day average 820,675, suggesting muted trading interest ahead of this news. normal

Technical Shares at 127.09 are trading below the 200-day MA of 138.3, reflecting a weaker intermediate trend.

Peers on Argus

RGEN fell 3.67% while key peers were mixed: STVN and TFX gained, BLCO and MMSI s...

1 Up

RGEN fell 3.67% while key peers were mixed: STVN and TFX gained, BLCO and MMSI slipped modestly. Only STVN showed notable momentum in scanners, suggesting RGEN’s move was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: 2026-03-05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-03-05	Conference participation	Positive	-0.6%	Announcement of participation in three March 2026 investor conferences.
2026-02-24	Earnings and guidance	Positive	-0.5%	Reported 2025 revenue growth and issued higher 2026 revenue guidance.
2026-02-10	Earnings date notice	Neutral	-0.4%	Set reporting date and call details for Q4 and full-year 2025 results.
2026-01-06	Leadership transition	Neutral	+1.7%	Announced board chair transition and advisor role for outgoing Executive Chair.
2025-12-18	Conference presentation	Positive	+0.5%	Planned presentation at J.P. Morgan 2026 Healthcare Conference.

Pattern Detected

Recent news, including positive earnings and conference updates, often saw modest or negative price reactions, indicating a pattern of muted responses to announcements.

Recent Company History

Over the last several months, Repligen has focused on investor visibility and governance while delivering growth. Earnings on 2026-02-24 highlighted $738M 2025 revenue and higher 2026 guidance, yet the stock slipped slightly afterward. Board leadership changes announced on 2026-01-06 drew a small positive move. Multiple conference appearances in late 2025 and early 2026 saw limited price impact, suggesting announcements alone have not driven large swings.

Market Pulse Summary

This announcement highlights Repligen’s continued build-out of its global Training & Innovation Cent...

Analysis

This announcement highlights Repligen’s continued build-out of its global Training & Innovation Center network, adding a third site in Breda to complement Waltham and Tokyo. The center showcases upstream and downstream bioprocessing technologies for biopharma and CDMO customers. In the backdrop, Repligen recently reported $738M in 2025 revenue and set 2026 guidance, so investors may watch how expanded customer proximity translates into future growth and product adoption.

Key Terms

pre-packed chromatography columns, bioprocessing, upstream intensification, hollow fiber filters, +4 more

8 terms

pre-packed chromatography columns medical

"OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands."

Pre-packed chromatography columns are ready-to-use tubes filled with a solid material that separates desired molecules (like proteins or drugs) from a mixture, similar to buying a pre-filled coffee filter instead of measuring grounds yourself. For investors, they matter because they speed up production, reduce variation and contamination risk, and simplify regulatory validation, which can lower manufacturing costs, shorten time to market and make biopharma processes more reliable and scalable.

bioprocessing medical

"hands-on experience with Repligen’s innovative bioprocessing solutions."

Bioprocessing is the set of manufacturing steps that use living cells or biological ingredients to make medicines, vaccines, diagnostics, or other biological products. Think of it as an assembly line where living systems, rather than machines, create the final product; variations in scale, consistency and cost directly affect a product’s ability to reach patients and generate revenue. Investors watch bioprocessing for its impact on production risk, regulatory approval and profit margins.

upstream intensification medical

"Upstream intensification technologies on display include XCell® ATF and KrosFlo® TFDF® devices"

Upstream intensification describes a company increasing activity or investment at the early stages of a product’s lifecycle—such as exploration and production in energy, raw-material sourcing in manufacturing, or research and discovery in biotech—to produce more or better inputs. Investors care because shifting resources earlier in the chain can change cost structures, boost long-term supply and revenues, or raise short-term capital needs and operational risk; think of it as widening the farm that feeds a factory.

hollow fiber filters medical

"Downstream offerings include OPUS® pre‑packed chromatography columns, Spectrum® hollow fiber filters"

Hollow fiber filters are tiny straw-like tubes with porous walls used to separate, concentrate or purify liquids by letting fluids pass through the walls while catching particles, cells or unwanted molecules. In biotech and pharmaceutical manufacturing they speed up production, improve product purity and help meet regulatory quality standards, so their performance and reliability can directly affect a company’s costs, output and risk profile — important factors for investors.

affinity resins medical

"TangenX® flat sheet cassettes, and affinity resins."

Affinity resins are solid beads or materials coated with a specific “bait” that selectively grabs a targeted molecule, such as a protein or antibody, out of a complex liquid. Think of them like a fishing lure that pulls only one kind of fish from a pond. For investors, they matter because they are central to drug and biologic manufacturing purity, yield and cost—differences in resin performance or supply can affect production efficiency, regulatory approval and company margins.

chromatography system medical

"including the KRM™ 10 Chromatography System, KrosFlo® RS 10 and RS30 RPM™ TFF Systems"

A chromatography system is a laboratory instrument that separates and measures different substances in a mixture by passing them through materials that slow some components more than others, like a sieve or filter that sorts mixed ingredients. For investors, it matters because these systems are essential for purifying drugs, verifying product quality, meeting regulatory standards, and scaling manufacturing; their performance affects costs, timelines, and the reliability of results that underpin commercial and regulatory decisions.

tff systems medical

"KrosFlo® RS 10 and RS30 RPM™ TFF Systems, and KrosFlo® KR2i RPM™ TFF System"

TFF systems are equipment that clean, concentrate or separate biological products by flowing liquid across a fine filter so material you want stays in the stream while unwanted parts are washed away—think of sweeping a sieve so it doesn’t clog. Investors care because these systems are central to how many drugs and vaccines are manufactured: they affect production speed, yield, purity and cost, and can influence a maker’s ability to scale and meet regulatory standards.

analytical solutions technical

"Also on display will be the PATsmart™ Upstream and Downstream Analytical Solutions"

Analytical solutions are tools, software, or services that collect and interpret raw data to produce clear, actionable insights—like a smart appliance that turns a pile of ingredients into a ready-to-cook meal. For investors, these solutions matter because they can turn complex information into repeatable products or subscriptions, improving a company’s ability to scale, generate steady revenue, and gain a competitive edge by helping customers make faster, better decisions.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen’s innovative bioprocessing solutions.

The Breda RTIC is Repligen’s third global training and innovation center, joining existing locations in Waltham, Massachusetts and Tokyo, Japan. The Breda opening event, held on April 15th, welcomed key biopharma and CDMO customers and highlighted Repligen’s continued investment in customer proximity and global support capabilities.

Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We are excited to open our third RTIC in Breda. The center provides a site for workshops and hands-on training for our technical teams and customers, while also highlighting our increasingly broad and diversified portfolio and end-to-end bioprocessing capabilities. Alongside recent investments in Asia Pacific and continued investment in the U.S., this opening underscores our commitment to serving customers globally.”

The Breda RTIC enables the functional display of all Repligen bioprocessing technologies; a complete collection from across the company’s global manufacturing sites. Upstream intensification technologies on display include XCell® ATF and KrosFlo® TFDF® devices and controllers. Downstream offerings include OPUS® pre‑packed chromatography columns, Spectrum® hollow fiber filters, TangenX® flat sheet cassettes, and affinity resins. There will be a number of systems on permanent display, including the KRM™ 10 Chromatography System, KrosFlo® RS 10 and RS30 RPM™ TFF Systems, and KrosFlo® KR2i RPM™ TFF System, highlighting the Company’s growing capital equipment offerings. Also on display will be the PATsmart™ Upstream and Downstream Analytical Solutions and Fluid Management products including ProConnex® MixOne RG-X and ProConnex® MixOne CB-X systems and flow paths, non-metallic equipment and a number of valve, clamp and tubing technologies.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

FAQ

What did Repligen (RGEN) announce about the Breda RTIC on April 17, 2026?

Repligen announced the opening of a new RTIC at its Breda OPUS manufacturing site to support customers with hands-on training. According to the company, the April 15 event welcomed biopharma and CDMO customers and underscores expanded global customer support capabilities.

How does the Breda RTIC expand Repligen’s global training network (RGEN)?

The Breda RTIC becomes Repligen’s third global center alongside Waltham and Tokyo, increasing regional access to training. According to the company, it provides local workshops, demonstrations and pre- and post-sales technical support for customers in Europe and nearby markets.

Which Repligen technologies are displayed at the Breda RTIC (RGEN)?

The Breda center displays upstream and downstream systems including XCell ATF, KrosFlo TFDF devices, OPUS columns and Spectrum filters. According to the company, capital equipment like KRM 10 and KrosFlo RPM TFF systems and PATsmart analytical solutions are on permanent display.

What customer benefits does Repligen (RGEN) say the Breda RTIC provides?

The company says the Breda RTIC offers hands-on workshops, demonstrations and pre-/post-sales support to improve technical adoption and proximity. According to the company, the center aims to accelerate customer training and showcase end-to-end bioprocessing workflows.

When was the Breda RTIC opening event and who attended, according to Repligen (RGEN)?

The Breda RTIC opening event took place on April 15, 2026 and hosted key biopharma and CDMO customers. According to the company, the event highlighted ongoing investments in Asia Pacific, U.S. and global customer support capabilities.